BeiGene has begun dosing in a Phase II clinical trial of its investigational drug candidate BGB-3111 for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in China.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

BGB-3111 is a potent and highly selective, investigational, small-molecule BTK inhibitor.

The single-arm, open-label, multi-centre Phase II trial will evaluate the efficacy and safety of BGB-3111 in patients with relapsed or refractory CLL / SLL.

BeiGene chairman and chief executive officer John Oyler said: “We are pleased to announce the start of the second pivotal clinical trial of BGB-3111 in China.

See Also:

"With this trial, we hope to demonstrate BGB-3111’s efficacy and safety in Chinese patients with CLL / SLL and build upon the promising data we presented at last year’s ASH annual meeting from the global Phase I trial of BGB-3111 in patients with CLL / SLL."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We are pleased to announce the start of the second pivotal clinical trial of BGB-3111 in China."

The primary endpoint of the trial is the objective response rate, defined as achievement of either a partial response or complete response at any time on study drug.

The trial will also demonstrate secondary endpoints such as progression-free survival, duration of response, time to response, safety and tolerability.

BGB-3111 is being further studied in a Phase II trial in Chinese patients with relapsed or refractory mantle cell lymphoma (MCL) and a global Phase III clinical trial to treat patients with Waldenström’s Macroglobulinemia compared to ibrutinib.

With operations in China, the US, Australia and Taiwan, BeiGene primarily develops molecularly targeted and immuno-oncology cancer therapeutics.

Image: Small Lymphocytic Lymphoma. Photo: courtesy of Ed Uthman/Wikipedia.